# Liminatus Pharma, Inc.: financial statements, quarterly

LIMN · Nasdaq · CIK 1971387 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/limn.md) · [Financials](/companies/limn/financials.md) · [Filings](/companies/limn/filings.md) · [Insiders](/companies/limn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/limn/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | not reported | [714](/filings/0001104659-25-096872.md) | [357](/filings/0001104659-25-111651.md) | [0.0 d](/filings/0001104659-26-037933.md) | not reported | not reported | not reported | not reported | [400](/filings/0001104659-26-062734.md) | [600](/filings/0001104659-26-097304.md) |
| Operating income | $k | [(0.2)](/filings/0001410578-25-001388.md) | [(909)](/filings/0001104659-25-096872.md) | [(543)](/filings/0001104659-25-111651.md) | [(167) d](/filings/0001104659-26-037933.md) | [(264)](/filings/0001104659-26-062734.md) | [(1,118)](/filings/0001104659-26-097304.md) | [(701)](/filings/0001104659-25-111651.md) | [(884) d](/filings/0001104659-26-037933.md) | [(1,101)](/filings/0001104659-26-062734.md) | [(1,379)](/filings/0001104659-26-097304.md) |
| Interest expense | $k | not reported | [77.2](/filings/0001104659-25-096872.md) | [92.7](/filings/0001104659-25-111651.md) | [106 d](/filings/0001104659-26-037933.md) | [116](/filings/0001104659-26-062734.md) | [62.3](/filings/0001104659-26-097304.md) | [19.1](/filings/0001104659-25-111651.md) | [19.1 d](/filings/0001104659-26-037933.md) | [18.6](/filings/0001104659-26-062734.md) | [18.8](/filings/0001104659-26-097304.md) |
| Net income | $k | [(1,754)](/filings/0001104659-25-111651.md) | [(961)](/filings/0001104659-25-111651.md) | [(601)](/filings/0001104659-25-111651.md) | [(230) d](/filings/0001104659-26-037933.md) | [(328)](/filings/0001104659-26-097304.md) | [113](/filings/0001104659-26-097304.md) | [(1,823)](/filings/0001104659-25-111651.md) | [(8,169) d](/filings/0001104659-26-037933.md) | [(1,124)](/filings/0001104659-26-097304.md) | [(1,407)](/filings/0001104659-26-097304.md) |
| Diluted EPS | $ per share | [(2.47)](/filings/0001410578-25-001388.md) | [(0.05)](/filings/0001104659-25-096872.md) | [(0.03)](/filings/0001104659-25-111651.md) | not reported | [(0.02)](/filings/0001104659-26-062734.md) | [0.00](/filings/0001104659-26-097304.md) | [(0.07)](/filings/0001104659-25-111651.md) | not reported | [(0.03)](/filings/0001104659-26-062734.md) | [(0.03)](/filings/0001104659-26-097304.md) |
| Basic EPS | $ per share | [(2.47)](/filings/0001410578-25-001388.md) | [(0.05)](/filings/0001104659-25-096872.md) | [(0.03)](/filings/0001104659-25-111651.md) | not reported | [(0.02)](/filings/0001104659-26-062734.md) | [0.00](/filings/0001104659-26-097304.md) | [(0.07)](/filings/0001104659-25-111651.md) | not reported | [(0.03)](/filings/0001104659-26-062734.md) | [(0.03)](/filings/0001104659-26-097304.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [0.1](/filings/0001104659-26-037933.md) | not reported | [1.3](/filings/0001104659-25-096872.md) | [0.7](/filings/0001104659-25-111651.md) | [0.3](/filings/0001104659-26-097304.md) | [1.9](/filings/0001104659-26-062734.md) | [3.0](/filings/0001104659-26-097304.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [5.3](/filings/0001104659-26-037933.md) | not reported | [1.8](/filings/0001104659-25-096872.md) | [1.2](/filings/0001104659-25-111651.md) | [0.5](/filings/0001104659-26-097304.md) | [2.8](/filings/0001104659-26-062734.md) | [3.4](/filings/0001104659-26-097304.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [5.4](/filings/0001104659-26-037933.md) | not reported | [1.9](/filings/0001104659-25-096872.md) | [1.3](/filings/0001104659-25-111651.md) | [0.5](/filings/0001104659-26-097304.md) | [2.8](/filings/0001104659-26-062734.md) | [3.4](/filings/0001104659-26-097304.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [24.7](/filings/0001104659-26-037933.md) | not reported | [10.5](/filings/0001104659-25-096872.md) | [2.9](/filings/0001104659-25-111651.md) | [10.3](/filings/0001104659-26-097304.md) | [2.9](/filings/0001104659-26-062734.md) | [3.0](/filings/0001104659-26-097304.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [24.7](/filings/0001104659-26-037933.md) | [0.0](/filings/0001410578-25-001388.md) | [10.7](/filings/0001104659-25-096872.md) | [3.0](/filings/0001104659-25-111651.md) | [10.3](/filings/0001104659-26-097304.md) | [2.9](/filings/0001104659-26-062734.md) | [3.1](/filings/0001104659-26-097304.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | [20.0](/filings/0001104659-26-037933.md) | not reported | [1.4](/filings/0001104659-25-096872.md) | [1.4](/filings/0001104659-25-111651.md) | [1.4](/filings/0001104659-26-097304.md) | [1.4](/filings/0001104659-26-062734.md) | [1.4](/filings/0001104659-26-097304.md) |
| Shareholders' equity | $m | [(15.8)](/filings/0001104659-26-037933.md) | [(17.5)](/filings/0001104659-25-111651.md) | [(18.5)](/filings/0001104659-25-111651.md) | [(19.1)](/filings/0001104659-25-111651.md) | [(19.3)](/filings/0001104659-26-097304.md) | [(19.7)](/filings/0001104659-26-097304.md) | [(8.8)](/filings/0001104659-26-097304.md) | [(1.6)](/filings/0001104659-25-111651.md) | [(9.8)](/filings/0001104659-26-097304.md) | [(0.1)](/filings/0001104659-26-097304.md) | [0.3](/filings/0001104659-26-097304.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [0.0](/filings/0001410578-25-001388.md) | [(1,104) d](/filings/0001104659-25-096872.md) | [(206) d](/filings/0001104659-25-111651.md) | [(141) d](/filings/0001104659-26-037933.md) | [(159)](/filings/0001104659-26-062734.md) | [(8,816) d](/filings/0001104659-26-097304.md) | [(601) d](/filings/0001104659-25-111651.md) | [(387) d](/filings/0001104659-26-037933.md) | [(2,015)](/filings/0001104659-26-062734.md) | [(970) d](/filings/0001104659-26-097304.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001104659-26-037933.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001410578-25-001388.md) | [17.5](/filings/0001104659-25-096872.md) | [17.5](/filings/0001104659-25-111651.md) | [17.5](/filings/0001104659-26-062734.md) | [23.3](/filings/0001104659-26-097304.md) | [27.0](/filings/0001104659-25-111651.md) | [36.0](/filings/0001104659-26-062734.md) | [48.4](/filings/0001104659-26-097304.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 67,160,362 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-097304.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.